Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study

The prognostic value of MRD in large series of childhood T-ALL has not yet been established. Trial AIEOP-BFM-ALL 2000 introduced standardized quantitative assessment of MRD for stratification, based on immunoglobulin and TCR gene rearrangements as polymerase chain reaction targets: Patients were considered MRD standard risk (MRD-SR) if MRD was negative at day 33 (time point 1 [TP1]) and day 78 (TP2), analyzed by at least 2 sensitive markers; MRD intermediate risk (MRD-IR) if positive either at day 33 or 78 and ; “Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia,” protocol identification #[NCT00430118][1] for BFM and #[NCT00613457][2] for AIEOP. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00430118&atom=%2Fbloodjournal%2F118%2F8%2F2077.atom [2]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00613457&atom=%2Fbloodjournal%2F118%2F8%2F2077.atom